drugset / Trial / NCT02156843
Pyridorin in Diabetic Nephropathy
Phase 3
Terminated
328 enrolled
NephroGenex, Inc.
Collaborative Study Group (CSG) · collabMedpace, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of oral Pyridorin 300 mg BID in reducing the rate of progression of nephropathy due to type 2 diabetes mellitus.
Timeline
- Start
- 2014-06
- Primary completion
- 2017-12
- Completion
- 2018-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyridorin | Unknown | 300 mg | Oral |